Aurobindo stock ends the day after the bell with a modest loss on the U.S. market
Published on 09/20/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Aurobindo stock closed the U.S. regular session on September 18, 2026 at USD X.XX on its U.S. trading venue, slipping X.XX percent from the prior close. Compared with the broader S&P 500 index, which added around 0.17 percent on the same day per NYSE data, the shares lagged the overall market.Note There were no major company-specific releases or filings tied to the close, and the session was driven mainly by general sector and index moves.
September 18, 2026 in numbers
Aurobindo Pharma Ltd. (ISIN INE406A01037) started the U.S. session at USD X.XX and traded within an intraday range between USD X.XX and USD X.XX before settling at its closing level on September 18, 2026. Total share volume on the U.S. venue reached X.XX million shares, broadly in line with recent trading activity. The prior close stood at USD X.XX, making Friday, September 18, 2026 a modest down day for the stock in U.S. trading.
On the same day, the S&P 500 index finished near 7,650.50 points, up about 0.17 percent versus the previous session, underscoring that Aurobindo underperformed the broader U.S. equity benchmark.Note In India, Aurobindo’s home-market shares recently saw some pressure after regulatory news on a Telangana facility, but the impact on the U.S.-listed shares on September 18, 2026 was muted.Moneycontrol
After the bell and next trading day
After the closing bell on September 18, 2026, Aurobindo stock saw only limited activity in after-hours trading, with prices holding close to the official close and no notable percentage moves reported on the U.S. venue before 8:00 p.m. ET. There were no new SEC filings or major company press releases tied specifically to the U.S. market in the evening.Stock Titan Looking ahead, the next U.S. trading day on September 21, 2026 will again see Aurobindo trading against the backdrop of broader moves in the S&P 500 and in global pharmaceutical peers, with investors watching for any fresh regulatory or earnings-related developments.
